Physician profile
Stephen M Cox
NPI 1275844847
$1,718.80
in general payments reported to CMS, 2019-2025
25 companies · $93.91 in 2025
The $93.91 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.98 · 2020: $132 · 2021: $149 · 2022: $139 · 2023: $551 · 2024: $581 · 2025: $93.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.15 | 2022-2024 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $239.09 | 2020-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $193.81 | 2020-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $141.83 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $129.67 | 2023-2024 | Freestyle Libre 2, Cardiomems, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $92.56 | 2024-2025 | |
| Lilly USA, LLC | $91.82 | 2019-2024 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $81.92 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $69.05 | 2019-2023 | Arexvy, Shingrix |
| Amgen INC. | $59.39 | 2020-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.60 | 2019-2022 | |
| Daiichi Sankyo INC. | $37.04 | 2022 | |
| Astellas Pharma US INC | $34.73 | 2023 | Myrbetriq, Veozah |
| Teva Pharmaceuticals USA, INC. | $30.25 | 2019 | |
| Lundbeck LLC | $27.65 | 2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $25.02 | 2020 | |
| Supernus Pharmaceuticals, INC. | $24.26 | 2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $19.01 | 2023 | Spravato |
| Inari Medical, INC. | $18.38 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $16.92 | 2021 | |
| Dynavax Technologies Corporation | $15.94 | 2021 | |
| Gilead Sciences, INC. | $14.68 | 2021 | |
| Pfizer INC. | $14.43 | 2024 | |
| Merck Sharp & Dohme LLC | $13.23 | 2020 | |
| Janssen Biotech, INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.